Celularity Inc
CELU2.220USD
+0.030+1.37%
Fechamento 09/19, 16:00（ET）Cotações atrasadas em 15 min
54.63MValor de mercado
PerdaP/L TTM
Mais detalhes de Celularity Inc Empresa
Celularity Inc. is a regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Interfyl and Rebound products. Its platform is Celularity IMPACT (Immuno-Modulatory Placental-derived Allogeneic Cell Therapy).
Informações da empresa
Código da empresaCELU
Nome da EmpresaCelularity Inc
Data de listagemMay 23, 2019
CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.
Número de funcionários123
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 23
Endereço170 Park Ave
CidadeFLORHAM PARK
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal07932
Telefone19087682170
Sitehttps://celularity.com/
Código da empresaCELU
Data de listagemMay 23, 2019
CEODr. Robert J. (Bob) Hariri, M.D., Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.85M
+0.12%
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Carlos Ramirez
Mr. Carlos Ramirez
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Mr. Vincent Levien
Mr. Vincent Levien
Director
Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.85M
+0.12%
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 3 de set
Atualizado em: qua, 3 de set
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Genting Bhd
23.74%
Hariri (Robert J)
10.70%
Starr International Company, Inc.
5.73%
Lincoln Alternative Strategies LLC
4.61%
Lung Biotechnology Inc
2.99%
Outro
52.25%
Investidores
Investidores
Proporção
Genting Bhd
23.74%
Hariri (Robert J)
10.70%
Starr International Company, Inc.
5.73%
Lincoln Alternative Strategies LLC
4.61%
Lung Biotechnology Inc
2.99%
Outro
52.25%
Tipos de investidores
Investidores
Proporção
Corporation
31.33%
Individual Investor
11.65%
Investment Advisor
8.46%
Insurance Company
2.86%
Investment Advisor/Hedge Fund
1.02%
Hedge Fund
0.34%
Research Firm
0.33%
Venture Capital
0.08%
Family Office
0.04%
Outro
43.88%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
104
15.80M
65.98%
-1.41M
2025Q1
140
16.18M
70.80%
+52.81K
2024Q4
156
14.05M
63.43%
-1.62M
2024Q3
169
14.41M
66.16%
-2.07M
2024Q2
181
15.12M
69.86%
-663.91K
2024Q1
187
14.36M
66.56%
-1.48M
2023Q4
186
12.31M
65.02%
-347.56K
2023Q3
186
12.52M
68.51%
+23.28K
2023Q2
200
12.33M
70.15%
-1.64M
2023Q1
224
13.36M
90.76%
-717.66K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Genting Bhd
6.34M
26.45%
--
--
May 15, 2025
Hariri (Robert J)
2.85M
11.92%
+3.28K
+0.12%
May 15, 2025
Starr International Company, Inc.
1.53M
6.38%
--
--
May 15, 2025
Lung Biotechnology Inc
796.88K
3.33%
--
--
Dec 31, 2023
C.V. Starr & Co., Inc.
764.07K
3.19%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
500.13K
2.09%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
136.04K
0.57%
+4.53K
+3.45%
Mar 31, 2025
Diamandis (Peter)
134.31K
0.56%
-63.82K
-32.21%
May 15, 2025
BlackRock Institutional Trust Company, N.A.
99.02K
0.41%
-471.00
-0.47%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Data
Tipo
Proporção
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
